BioArctic's LEQEMBI Wins Awards, Eisai Expects Revenue, and New Data on Subcutaneous Formulation

BioArctic's LEQEMBI (LEQEMBI) wins two categories at The Scrip Awards 2023, including Best New Drug and Clinical Advance of the Year. Eisai expects Leqembi to generate revenue of $66.5 million by March 2024. Eisai and Biogen present new data on the subcutaneous formulation of LEQEMBI, showing it clears amyloid plaques more effectively than intravenous infusion. BioArctic and Eisai are preparing for a joint commercialization in the Nordics.